1. Home
  2. SCLX vs ASRT Comparison

SCLX vs ASRT Comparison

Compare SCLX & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scilex Holding Company

SCLX

Scilex Holding Company

HOLD

Current Price

$8.05

Market Cap

90.0M

Sector

Health Care

ML Signal

HOLD

Logo Assertio Holdings Inc.

ASRT

Assertio Holdings Inc.

HOLD

Current Price

$11.79

Market Cap

76.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCLX
ASRT
Founded
2011
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
90.0M
76.0M
IPO Year
N/A
2004

Fundamental Metrics

Financial Performance
Metric
SCLX
ASRT
Price
$8.05
$11.79
Analyst Decision
Hold
Strong Buy
Analyst Count
1
1
Target Price
N/A
$35.00
AVG Volume (30 Days)
41.4K
35.1K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
95.07
EPS
N/A
N/A
Revenue
N/A
$124,961,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$749.70
$1.42
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.18
$0.51
52 Week High
$34.27
$12.95

Technical Indicators

Market Signals
Indicator
SCLX
ASRT
Relative Strength Index (RSI) 37.66 56.76
Support Level $7.82 $0.67
Resistance Level $12.30 $12.75
Average True Range (ATR) 0.63 0.54
MACD 0.19 -0.24
Stochastic Oscillator 28.25 28.03

Price Performance

Historical Comparison
SCLX
ASRT

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

About ASRT Assertio Holdings Inc.

Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.

Share on Social Networks: